what announcement next, page-10

Re: a partner here is an extract of a post by TDA (6963558) from 20 July 2011

"HA-irinotecan is hyaluronic acid (HA) combined with Pfizer?s [NYSE:PFE] generic chemotherapy Camptosar (irinotecan). Regulatory experts previously told this news service that unless new formulations of generic drugs in oncology settings demonstrate superiority over existing generics and treatment regimes, they may face a tough regulatory process. Alchemia hopes to achieve at least a six week progression-free survival (PFS) advantage over Camptosar in Phase III, it was previously reported.
Alchemia intends to partner at the end of Phase III as it believes this will be the optimal time to strike a valuable deal, noted Smith. ?We also like the fact that we will own 100% of the product at that point,? he said.
Alchemia will start talks with potential partners once recruitment starts, partly to keep them informed of the progress, but also to explore regional deals and opportunities to get other reformulated drugs moving forward, said Smith."